Experimental drug offers hope for rare cancer patients Who've run out of options
NCT ID NCT07324629
Summary
This study is testing whether a new drug called sacituzumab tirumotecan (Sac-TMT) can help control advanced thymic cancer that has worsened after standard chemotherapy. About 30 adults with this rare cancer will receive the drug every two weeks to see if it shrinks tumors and how long the benefit lasts. Researchers will closely monitor participants for side effects and how well the cancer responds to treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.